This morning we watched DexCom drop -2.0% to a price of $104.7 per share. The large-cap Medical Instruments & Supplies company is now trading -28.98% below its average target price of $147.42. Analysts have set target prices ranging from $130.0 to $160.0 per share for DexCom, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 4.9%, and a short ratio of 4.75. The company's insiders own 0.39% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.7% of DexCom's shares being owned by this investor type.
Institutions Invested in DexCom
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 11% | 44,283,991 | $4,636,755,358 |
| 2023-06-30 | Blackrock Inc. | 9% | 33,254,953 | $3,481,959,914 |
| 2023-06-30 | Baillie Gifford and Company | 4% | 16,723,298 | $1,751,012,947 |
| 2023-06-30 | State Street Corporation | 4% | 16,543,092 | $1,732,144,478 |
| 2023-06-30 | Sands Capital Management, LLC | 3% | 13,103,127 | $1,371,962,936 |
| 2023-06-30 | JP Morgan Chase & Company | 3% | 12,673,177 | $1,326,945,020 |
| 2023-06-30 | FMR, LLC | 3% | 10,581,207 | $1,107,905,298 |
| 2023-06-30 | Capital Research Global Investors | 2% | 9,116,546 | $954,547,965 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 8,557,578 | $896,021,220 |
| 2023-06-30 | Nuveen Asset Management, LLC | 2% | 7,934,150 | $830,745,190 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on DexCom.
